On March 2, 2026, the U.S. Food and Drug Administration removed the clinical hold on Intellia Therapeutics’ MAGNITUDE Phase 3 trial—restarting a program that had been frozen since late October after a fatal liver event.
If you only read the headline, it sounds like a clean win: the FDA pressed “play,” investors exhaled, and CRISPR got another chance to prove it can be medicine—not just molecular biology.
But the more important story is quieter: the hold didn’t end with a verdict; it ended with a new operating manual.
Because this is what modern drug development looks like when a therapy is both (1) potentially transformative and (2) essentially irreversible.
